Adalvo has successfully completed the pivotal fed study for Avatrombopag 20 mg film-coated tablets.
This milestone supports the progression towards regulatory submission and Day-1 launches across the US, EU and other key global markets.
Avatrombopag is indicated to treat adults with primary chronic immune thrombocytopenia (ITP) and thrombocytopenia in adults with chronic liver disease (CLD).
In patients with ITP or CLD, dangerously low platelet counts create a significant bleeding risk, especially if they’re due to undergo a surgical or invasive procedure. Avatrombopag works by mimicking thrombopoietin, the body's natural platelet-production signal, stimulating bone marrow to generate platelets the body is failing to produce on its own.
Avatrombopag addresses two distinct clinical needs: ongoing platelet management in ITP patients, and short-course pre-procedural support for CLD patients facing surgery — demonstrating the breadth of application from a single molecule.
For partners, the successful BE study represents a clear advancement towards a high-quality, market-ready asset supported by a well-defined IP pathway.
To explore licensing opportunities or discuss adding Avatrombopag to your portfolio, contact our team today.